We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+63.92%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
+$364M
Cap. Flow
+$152M
Cap. Flow %
10.45%
Top 10 Hldgs %
51.41%
Holding
99
New
31
Increased
26
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$65.2M
2
ABVX
Abivax
ABVX
+$26.1M
3
QURE icon
uniQure
QURE
+$15.9M
4
DHR icon
Danaher
DHR
+$15.1M
5
PODD icon
Insulet
PODD
+$14.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$43.8M
2
INSP icon
Inspire Medical Systems
INSP
+$21.3M
3
IQV icon
IQVIA
IQV
+$15.4M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$15.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.94%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRRO icon
76
Korro Bio
KRRO
$153M
$999K 0.07%
+20,856
New +$463K
SRZN icon
77
Surrozen
SRZN
$229M
$992K 0.07%
+76,997
New +$807K
PNTG icon
78
Pennant Group
PNTG
$1.43B
$958K 0.07%
37,980
– –
MRVI icon
79
Maravai LifeSciences
MRVI
$997M
$834K 0.06%
290,673
-350,000
-55% -$894K
PVLA
80
Palvella Therapeutics
PVLA
$1.98B
$711K 0.05%
+11,343
New +$506K
EHTH icon
81
eHealth
EHTH
$42.5M
$553K 0.04%
128,322
– –
ATYR
82
PUT
aTyr Pharma
ATYR
$46.4M
$475K 0.03%
+658,000
New +$2.98M
RVP icon
83
Retractable Technologies
RVP
$20.4M
$306K 0.02%
+363,315
New +$278K
REPL icon
84
Replimune Group
REPL
$814M
$251K 0.02%
+59,992
New +$383K
CBLL
85
CeriBell Inc
CBLL
$642M
$196K 0.01%
+17,094
New +$231K
DYN icon
86
Dyne Therapeutics
DYN
$4.04B
$127K 0.01%
+10,000
New +$114K
ACIU icon
87
AC Immune
ACIU
$227M
– –
-100,752
Closed -$205K
ARCT icon
88
Arcturus Therapeutics
ARCT
$157M
– –
-48,364
Closed -$629K
AUTL
89
Autolus Therapeutics
AUTL
$386M
– –
-610,231
Closed -$1.39M
GKOS icon
90
Glaukos
GKOS
$9.02B
– –
-31,496
Closed -$3.25M
GMED icon
91
Globus Medical
GMED
$10.4B
– –
-169,643
Closed -$10M
INSP icon
92
Inspire Medical Systems
INSP
$1.42B
– –
-164,473
Closed -$21.3M
IQV icon
93
IQVIA
IQV
$34.7B
– –
-97,604
Closed -$15.4M
ITOS
94
DELISTED
iTeos Therapeutics
ITOS
– –
-109,324
Closed -$1.09M
KPTI icon
95
Karyopharm Therapeutics
KPTI
$168M
– –
-257,154
Closed -$1.11M
MODV
96
DELISTED
ModivCare
MODV
– –
-100,000
Closed -$312K
PBYI icon
97
Puma Biotechnology
PBYI
$406M
– –
-240,688
Closed -$826K
PTGX icon
98
Protagonist Therapeutics
PTGX
$8.75B
– –
-277,316
Closed -$15.3M
TMO icon
99
Thermo Fisher Scientific
TMO
$211B
– –
-13,685
Closed -$5.55M
1 2 3
4

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Eversept Partners held 99 positions worth $1.45B, up 33% from $1.09B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Eversept Partners deployed $152M of net new capital in Q3 2025, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Abivax: 426,499 shares worth $36.2M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $43.8M trimmed.

  • Eversept Partners's largest Q3 2025 buy was Abivax: 426,499 shares worth $36.2M.
  • Eversept Partners added most to United Therapeutics in Q3 2025, an estimated $65.2M increase.
  • Eversept Partners's biggest Q3 2025 reduction was Natera, cutting an estimated $43.8M.
  • Eversept Partners fully exited Inspire Medical Systems in Q3 2025, selling an estimated $21.3M.
  • Eversept Partners's ten largest holdings make up 51% of its $1.45B portfolio in Q3 2025.
  • Eversept Partners opened 31 new positions and closed 13 in Q3 2025.
  • Eversept Partners's portfolio value rose 33% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.